We are here to build next generation life science ventures. Scroll At XGEN we specialize in early stage investments in private research & development companies in the life sciences sector. XGEN Venture is an Italian alternative investment fund manager (Società di Gestione del Risparmio, or SGR) established in 2021 by the former Genextra team, with […]
Investment Stage: Pre-Seed; Seed; Series A; Series B
Portfolio 9
| Date | Name | Website | Total Raised | Location |
| 10.07.2026 | GESYNTA PH... | gesynta.se | $48.13M | Sweden |
| 10.07.2026 | Genespire | genespire.com | $69.18M | Italy, Lom... |
| 10.07.2026 | AAVantgard... | aavantgarde.com | $141M | - |
| 10.07.2026 | iOnctura | ionctura.com | $144.43M | Switzerlan... |
| 12.12.2025 | EpilepsyGT... | epilepsygtx.com | $43M | United Kin... |
| 07.11.2025 | AAVantgard... | aavantgardebio.com | $141M | Italy |
| 06.10.2025 | NANOPHORIA | nanophoria.com | $115.98M | Italy |
| 16.05.2024 | TES Pharma | tespharma.com | - | - |
| 16.05.2024 | Protembis | protembis.com | $64.35M | Germany, N... |
Mentions in press and media 18
| Date | Title | Description |
| 17.06.2026 | Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat | Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat Wed, Jun 17, 2026 09:00 CET Report this content STOCKHOLM, SWEDEN – June 17, 2026. Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company f... |
| 17.06.2026 | Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat | STOCKHOLM, June 17, 2026 /PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase ... |
| 17.03.2026 | /C O R R E C T I O N -- Gesynta Pharma/ | In the news release, First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat, issued 11-Mar-2026 by Gesynta Pharma over PR Newswire, the source was erroneously mentioned as Getinge Group rather than as Gesynta Pharma as ... |
| 11.03.2026 | First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat | STOCKHOLM, March 11, 2026 /PRNewswire/ -- Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for end... |
| 15.12.2025 | EpilepsyGTx Secures $33M to Pioneer Single-Dose Gene Therapy for Refractory Epilepsy | EpilepsyGTx just raised $33 million. This Series A funding will fuel clinical trials. Their focus? A gene therapy for focal refractory epilepsy (FRE). FRE impacts millions globally. Current treatments often fail. EpilepsyGTx offers a potent... |
| 12.12.2025 | EpilepsyGTx Secures $33 Million Series A To Advance Single-Dose Gene Therapy For Focal Refractory Epilepsy | EpilepsyGTx, a biotechnology company focused on developing gene therapies for refractory epilepsy, has raised $33 million in a Series A financing to advance its lead program, EPY201, into first-in-human clinical trials. The funding will sup... |
| 10.12.2025 | EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy | Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidate EPY201 targeting focal refractory epilepsy (FRE) Future financings to adva... |
| 10.12.2025 | Gene therapy for severe epilepsy moves forward with EpilepsyGTx’s €28 million funding | EpilepsyGTx, a Cambridge-based BioTech startup focused on research and development of gene therapies to treat refractory epilepsy, today announced it has raised €28 million ($33 million) in Series A financing to advance its lead programme E... |
| 08.11.2025 | AAVantgarde Secures $141M for Groundbreaking Gene Therapies | AAVantgarde Bio closed a $141 million Series B round. This substantial funding propels gene therapy programs for inherited retinal diseases. Key targets: Stargardt disease and Usher Syndrome Type 1B. Both represent severe conditions with no... |
| 07.11.2025 | AAVantgarde: $141 Million Series B Closed To Advance Clinical Programs For Stargardt Disease And Usher 1B Syndrome | AAVantgarde Bio has closed a $141 million (€122 million) Series B financing to advance its lead clinical programs targeting inherited retinal diseases. The financing round was co-led by Schroders Capital, Atlas Venture, and Forbion, with pa... |
Show more